Previous Close | 1.4900 |
Open | 1.4700 |
Bid | 1.4600 x 600 |
Ask | 1.4900 x 100 |
Day's Range | 1.4600 - 1.5050 |
52 Week Range | 0.7100 - 1.9600 |
Volume | |
Avg. Volume | 1,106,918 |
Market Cap | 263.091M |
Beta (5Y Monthly) | 0.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1400 |
Earnings Date | Apr 30, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.46 |
Subscribe to Yahoo Finance Plus to view Fair Value for RIGL
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background.
Key Financial Highlights from Rigel's Earnings Report
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript March 5, 2024 Rigel Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023. […]